Drug addiction

Study Shows GLP-1 Drugs Could Be Linked to Lower Addiction Risk

Do GLP-1 drugs biologically treat addiction or do results simply reflect healthier patient behavior patterns?

Published MAR 5

Study Shows GLP-1 Drugs Could Be Linked to Lower Addiction Risk

Story

Above: Wegovy tablets and Ozempic injection pens. Image credit: Michael Siluk/UCG/Universal Images Group/Getty Images

The Facts

Research published in the British Medical Journal analyzed health records from 606,434 U.S. veterans with type 2 diabetes who were prescribed either GLP-1 receptor agonists or SGLT2 inhibitors and monitored for up to three years.
Daily Mail
BMJ
Among veterans with no history of substance abuse, starting a GLP-1 drug was associated with reduced risk of developing substance use disorders, including an 18% reduction for alcohol, 14% for cannabis, 20% for cocaine and nicotine and 25% for opioids.
The Telegraph
Time
For people with existing substance use disorders, GLP-1 receptor agonists were linked to 50% fewer substance-related deaths, 39% fewer drug overdoses, 26% fewer hospital admissions and 31% lower risk of emergency department visits over three years.
guardian
CNN
GLP-1 receptors are expressed in brain regions involved in reward, motivation and addiction, and at therapeutic doses these drugs cross the blood-brain barrier to modulate dopamine signaling in pathways that addictive substances exploit.
The Conversation
BMJ
Researchers noted that many questions remain about GLP-1 drugs and addiction, including whether cravings return when people discontinue the medications and whether the brain develops tolerance that reduces the drugs' effectiveness over prolonged use.
STAT
Time

Sources Split

LEFT

CENTER

RIGHT

ESTAB
CRIT

CENTER

PRO
ESTAB

The Spin

Narrative A

It's an extremely positive development that these drugs quiet the relentless craving that drives addiction by targeting shared reward pathways in the brain, offering hope where decades-old treatments have failed miserably. This isn't about willpower anymore; it's about treating addiction as the chronic biological disease it actually is.

STAT

Scientific American

Narrative B

This study suffers from adherer bias, as GLP-1 patients are simply more motivated and healthcare-engaged than comparison groups in ways no statistical adjustment can fix. Finding uniform protection across every tested substance screams confounding rather than a genuine drug effect.

Dr. Rick Barnett, PsyD on X